Recce Pharmaceuticals Ltd (ASX:RCE)
Australia · Delayed Price · Currency is AUD | Market Cap | 100.90M -15.9% |
| Revenue (ttm) | 9.47M +26.1% |
| Net Income | -14.96M |
| EPS | -0.05 |
| Shares Out | 305.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,196 |
| Open | 0.3300 |
| Previous Close | 0.3300 |
| Day's Range | 0.3300 - 0.3300 |
| 52-Week Range | 0.2650 - 0.7300 |
| Beta | 0.49 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 4, 2026 |
About Recce Pharmaceuticals
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is in Phase II clinical trial for the treatment of acute bacterial skin and skin structure inf... [Read more]
Financial Performance
In fiscal year 2026, Recce Pharmaceuticals's revenue was 9.47 million, an increase of 26.06% compared to the previous year's 7.51 million. Losses were -14.96 million, -30.18% less than in 2025.
Financial StatementsNews
Recce Pharmaceuticals Slides: FY 2026
Recce Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 4, 2026.
Recce Pharmaceuticals Earnings release: Q1 2027
Recce Pharmaceuticals released its Q1 2027 earnings on October 29, 2026, summarizing the period's financial results.
Recce Pharmaceuticals Annual report: H2 2026
Recce Pharmaceuticals has published its H2 2026 annual report on September 1, 2026.
Recce Pharmaceuticals Slides: Investor presentation
Recce Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 31, 2026.
Recce Pharmaceuticals Slides: Corporate presentation
Recce Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 2, 2026.
Recce Pharmaceuticals Slides: Investor presentation
Recce Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2026.
Recce Pharmaceuticals Slides: Corporate presentation
Recce Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Recce Pharmaceuticals Transcript: Investor update
A novel broad-spectrum antibiotic gel is in late-stage trials for diabetic foot infections, with commercial launch targeted for 2024 in Indonesia and ASEAN. Strong clinical and preclinical data, global partnerships, and U.S. Department of Defense support position the product for rapid market expansion and leadership in anti-infectives.
Recce Pharmaceuticals Quarterly report: H1 2026
Recce Pharmaceuticals has published its H1 2026 quarterly earnings report on February 26, 2026.